Regenxbio Historical Cash Flow
| RGNX Stock | USD 10.01 0.46 4.82% |
Analysis of Regenxbio cash flow over time is an excellent tool to project Regenxbio future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 34.7 M or Change To Liabilities of 21.3 M as it is a great indicator of Regenxbio ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Regenxbio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regenxbio is a good buy for the upcoming year.
Regenxbio |
About Regenxbio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Regenxbio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Regenxbio's non-liquid assets can be easily converted into cash.
Regenxbio Cash Flow Chart
Add Fundamental
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Regenxbio's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Regenxbio current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.At this time, Regenxbio's Change To Inventory is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 106.4 M in 2024, despite the fact that Change In Cash is likely to grow to (59.3 M).
| 2023 | 2024 (projected) | Stock Based Compensation | 40.3M | 23.8M | Net Borrowings | 2.2M | 1.9M |
Regenxbio cash flow statement Correlations
Click cells to compare fundamentals
Regenxbio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regenxbio cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 5.3M | 2.4M | 17.9M | 29.3M | 33.7M | 35.4M | |
| Change In Cash | (5.8M) | 268.9M | 7.5M | (248.3M) | (62.4M) | (59.3M) | |
| Free Cash Flow | (119.4M) | (80.9M) | 134.7M | (238.2M) | (228.4M) | (216.9M) | |
| Change In Working Capital | (5.3M) | 14.2M | 40.2M | 14.0M | (10.9M) | (10.3M) | |
| Begin Period Cash Flow | 76.6M | 70.8M | 339.8M | 347.2M | 99.0M | 106.4M | |
| Other Cashflows From Financing Activities | (1.3M) | 198.4M | (23.0M) | (30.6M) | (40.6M) | (38.6M) | |
| Other Non Cash Items | (2.7M) | (1.2M) | 4.4M | 5.2M | (1.6M) | (1.5M) | |
| Capital Expenditures | 11.7M | 26.9M | 84.2M | 30.7M | 10.0M | 19.3M | |
| Total Cash From Operating Activities | (107.7M) | (54.1M) | 218.9M | (207.5M) | (218.4M) | (207.5M) | |
| Change To Account Receivables | (8.6M) | (9.9M) | 14.1M | 4.8M | 3.9M | 4.1M | |
| Net Income | (94.7M) | (111.3M) | 127.8M | (280.3M) | (263.5M) | (250.3M) | |
| Total Cash From Financing Activities | 8.4M | 200.2M | 195.3M | (28.8M) | (35.0M) | (33.2M) | |
| End Period Cash Flow | 70.8M | 339.8M | 347.2M | 99.0M | 36.6M | 34.7M | |
| Change To Liabilities | 7.3M | 20.0M | (3.2M) | 17.6M | 20.3M | 21.3M | |
| Sale Purchase Of Stock | 1.3M | 1.8M | (2K) | (284K) | (419K) | (398.1K) | |
| Investments | 105.3M | 147.3M | (322.5M) | (11.9M) | 183.7M | 192.9M | |
| Stock Based Compensation | 26.9M | 31.9M | 38.8M | 40.8M | 40.3M | 23.8M | |
| Total Cashflows From Investing Activities | 93.6M | 122.8M | (406.6M) | (11.9M) | (13.7M) | (14.4M) | |
| Depreciation | 7.2M | 8.4M | 9.6M | 12.9M | 17.3M | 18.2M | |
| Change To Operating Activities | 2.4M | 20.2M | 29.3M | (8.5M) | (9.7M) | (9.3M) | |
| Other Cashflows From Investing Activities | 2.4M | (266.1M) | 105.3M | 2.3M | 2.6M | 2.8M | |
| Change To Netincome | 21.1M | 40.6M | 41.3M | 45.9M | 52.8M | 55.5M | |
| Change Receivables | (16.8M) | (8.6M) | (9.9M) | 14.1M | 16.2M | 17.0M | |
| Cash And Cash Equivalents Changes | 29.7M | (5.8M) | 268.9M | 7.5M | 8.6M | 8.2M | |
| Cash Flows Other Operating | (8.9M) | (38.7M) | (3.0M) | (1.3M) | (1.1M) | (1.2M) | |
| Issuance Of Capital Stock | 1.6M | 1.8M | 216.4M | 1.7M | 6.7M | 6.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.